
When Patients Win, Everyone Wins
When was the last time you asked a patient to contribute to trial design? Have you ever asked a patient to contribute to a protocol? Patient-centricity benefits the entire healthcare ecosystem.
When was the last time you asked a patient to contribute to trial design? Have you ever asked a patient to contribute to a protocol? Patient-centricity benefits the entire healthcare ecosystem.
To conduct meaningful research, we must be sure to view these studies through patients’ eyes. The patient perspective — in all its diversity — must be embedded into clinical trials from the very start.
Solving three major challenges in the development of new oncology drugs
Game-changing advances can be achieved by integrating patient collaboration and priorities into the full span of trial design.
Clinical trial design will be one of the topics discussed at the upcoming INVEST Digital Health conference in Dallas on October 26. THREAD Clinical Trial Design Director Noah Goodson highlighted some of the milestones the sector has seen in recent years.
The paradigm shift to more patient-centric, technology-enabled decentralized clinical trials during the pandemic has created an opportunity to strengthen patient care in research.
I’m tired of hearing the phrase, “after-Covid.” We know that in the next few months the first major wave in North America will be over, but there is no going back to the way life was on March 15. Certainly not immediately, and maybe not ever. There’s no magic switch that will allow us to […]
Reducing trial timelines has to be a long-term industry imperative, and digital technology can help valuable research continue to move forward while keeping participants safe.
Experimental models such as virtual clinical trials are designed with patient-generated data in mind.
One goal of FocalView is to create a more accurate way to track and measure disease progression and develop more sensitive clinical trial endpoints from the comfort of patients' homes., adding more flexibility to clinical trial design.
The analysis said that the consent forms signed by the women did not mention a clinical trial.
There is enormous untapped potential in the N-of-1 clinical trial.